15/03/2026
COVERSE has just submitted to the USA Advisory Committee on Immunization Practices, ahead of an upcoming meeting within the US Centers for Disease Control and Prevention.
The reason this was important is that the Australian case study offers one of the clearest national data sets of COVID-19 vaccine reactions. Australian states had zero or near-zero community transmission when vaccine rollouts commenced, enabling unusual clarity around adverse events, in clear timelines, via both clinical data and patient experiences.
The ACIP agenda includes discussion of COVID-19 vaccine injuries, Long-COVID, and vaccine recommendation methodologies, issues that shape clinical guidance and safety monitoring in the United States, with global implications.
Secondly, this was important because Australia is heavily influenced by U.S. regulatory systems. Most vaccine manufacturers are U.S.-domiciled, meaning U.S. clinical trials, approvals and safety monitoring directly affect outcomes here.
By comparison, however, Australia has no active national research program investigating COVID-19 vaccine injury following the cancellation of the QoVAX study, and injured Australians face a far more limited compensation pathway than citizens in many other countries.
COVERSE will continue to support sincere international bipartisan efforts to address overdue scientific attention, pharmacovigilance improvements and regulatory reforms required for stronger vaccine safety measures, and renewed trust in public health.
To read our submission: https://www.regulations.gov/comment/CDC-2026-0199-2303
